📊 MBIO Key Takeaways
Is Mustang Bio, Inc.. (MBIO) a Good Investment?
Mustang Bio is a pre-revenue pharmaceutical company with zero sales, burning approximately $1M quarterly in operating losses. The balance sheet is heavily leveraged with $15.8M in long-term debt relative to only $8.6M in equity, creating significant financial constraint for a company still in development stages with an estimated 4-year cash runway at current burn rates.
Mustang Bio remains a pre-revenue biotech with no commercial revenue base, negative operating cash flow, and ongoing losses, so the core fundamentals still depend on external financing or clinical/commercial execution. Losses improved materially year over year and liquidity is currently adequate, but leverage is high relative to equity and the business has not yet demonstrated durable revenue-generating capacity.
Why Buy Mustang Bio, Inc.. Stock? MBIO Key Strengths
- Adequate cash position of $16.3M providing near-term operational runway
- Current ratio of 2.25x demonstrates short-term liquidity capacity
- Pre-revenue stage is typical for early-stage biotech with potential value if pipeline succeeds
- Net loss and diluted EPS improved significantly year over year
- Cash and equivalents of $17.27M support near-term liquidity
- Current and quick ratios of 2.22x indicate acceptable short-term balance sheet coverage
MBIO Stock Risks: Mustang Bio, Inc.. Investment Risks
- Zero revenue with no demonstrated commercial traction or market validation
- High leverage with 1.83x debt-to-equity ratio creates severe constraints if clinical trials fail or capital needs arise
- Persistent negative cash flow (-$1M operating cash burn) with limited financial flexibility to fund R&D or pivot strategy
- Negative interest coverage (-211.6x) indicates inability to service debt from operations; vulnerable to covenant violations or refinancing risk
- Estimated 4-year cash runway leaves minimal margin for pipeline setbacks, regulatory delays, or equity capital requirements
- Zero revenue means growth quality is weak and operations are not yet self-sustaining
- Negative operating cash flow and free cash flow indicate ongoing cash burn
- Debt-to-equity of 1.65x and deeply negative interest coverage reflect elevated financial risk
Key Metrics to Watch
- Operating cash flow trajectory and quarterly burn rate sustainability
- Clinical trial progress and FDA regulatory milestones for pipeline candidates
- Debt refinancing terms and covenant compliance given negative operating income
- Quarterly operating cash burn relative to cash balance
- Any transition from zero revenue to recurring product or collaboration revenue
Mustang Bio, Inc.. (MBIO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.25x current ratio provides a solid financial cushion.
MBIO Profit Margin, ROE & Profitability Analysis
MBIO vs Healthcare Sector: How Mustang Bio, Inc.. Compares
How Mustang Bio, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Mustang Bio, Inc.. Stock Overvalued? MBIO Valuation Analysis 2026
Based on fundamental analysis, Mustang Bio, Inc.. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Mustang Bio, Inc.. Balance Sheet: MBIO Debt, Cash & Liquidity
MBIO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Mustang Bio, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-38.57 indicates the company is currently unprofitable.
MBIO Revenue Growth, EPS Growth & YoY Performance
Mustang Bio, Inc.. Dividends, Buybacks & Capital Allocation
MBIO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Mustang Bio, Inc.. (CIK: 0001680048)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MBIO
What is the AI rating for MBIO?
Mustang Bio, Inc.. (MBIO) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MBIO's key strengths?
Claude: Adequate cash position of $16.3M providing near-term operational runway. Current ratio of 2.25x demonstrates short-term liquidity capacity. ChatGPT: Net loss and diluted EPS improved significantly year over year. Cash and equivalents of $17.27M support near-term liquidity.
What are the risks of investing in MBIO?
Claude: Zero revenue with no demonstrated commercial traction or market validation. High leverage with 1.83x debt-to-equity ratio creates severe constraints if clinical trials fail or capital needs arise. ChatGPT: Zero revenue means growth quality is weak and operations are not yet self-sustaining. Negative operating cash flow and free cash flow indicate ongoing cash burn.
What is MBIO's revenue and growth?
Mustang Bio, Inc.. reported revenue of $0.0.
Does MBIO pay dividends?
Mustang Bio, Inc.. does not currently pay dividends.
Where can I find MBIO SEC filings?
Official SEC filings for Mustang Bio, Inc.. (CIK: 0001680048) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MBIO's EPS?
Mustang Bio, Inc.. has a diluted EPS of $-0.14.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MBIO a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Mustang Bio, Inc.. has a SELL rating with 82% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MBIO stock overvalued or undervalued?
Valuation metrics for MBIO: ROE of -11.1% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MBIO stock in 2026?
Our dual AI analysis gives Mustang Bio, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MBIO's free cash flow?
Mustang Bio, Inc..'s operating cash flow is $-1.0M, with capital expenditures of $0.0.
How does MBIO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -11.1% (avg: 15%), current ratio 2.25 (avg: 2).
Is Mustang Bio, Inc.. carrying too much debt?
MBIO has a debt-to-equity ratio of 1.83x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 2.25 suggests adequate short-term liquidity.